Scientific insights:CKD
VibeOne analyzed 100+ CKD programs and found a clear pattern: small molecules dominate and repurposed drugs win. The next kidney breakthrough may already be in a cardiovascular trial.
Author: Alok Tayi
-
-
Scientific insights:The ActRIIB Challenge (LAE103)
The obesity market is undergoing a quiet revolution: it’s no longer about how much weight patients lose, but what kind of weight they lose.
-
Scientific insights: Urea cycle disorders
Drug hunters need to watch Urea Cycle Disorders! Gene therapies (cost) and ERTs (patient experience) still leave much to be desired.
-
Scientific insights: Kidney disease
Explore why kidney disease is emerging as a top therapeutic focus. See how VibeOne identifies high-potential kidney indications and guides strategic prioritization.
-
Scientific insights: Fabry disease
Fabry disease may seem niche, but it’s becoming a bellwether for how global innovation and modality shifts are reshaping rare disease pipelines.
-
From overwhelm to clarity: prioritizing assets with AI-powered confidence
Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose.
-
Modern biopharma BD: How to find the diamonds in the rough
Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and AI-powered asset tracking.
-
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization.
-
Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and probability assessment approaches.
-
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future.
